Results 1 to 10 of about 20,750 (203)

Impact of metabolic enzyme activity variability on dabrafenib disposition [PDF]

Frontiers in Pharmacology
IntroductionThe systemic exposure of dabrafenib correlates with its adverse drug reactions. A thorough understanding of its pharmacokinetic profile is crucial for precise clinical application.MethodsAn optimized liver microsomal incubation system was ...
Shi-yu Wang, Shi-yu Wang, Qing Chen, Zhong-xi Chen, Jing Chen, Jing Yuan, Li-shang Dai, Lian-guo Chen, Xiao-dan Zhang, Xiao-dan Zhang   +9 more
doaj   +2 more sources

Mechanistically Coupled PK (MCPK) Model to Describe Enzyme Induction and Occupancy Dependent DDI of Dabrafenib Metabolism

Pharmaceutics, 2022
Dabrafenib inhibits the cell proliferation of metastatic melanoma with the oncogenic BRAF(V600)-mutation. However, dabrafenib monotherapy is associated with pERK reactivation, drug resistance, and consequential relapse. A clinical drug-dose determination
Marco Albrecht, Yuri Kogan, Dagmar Kulms, Thomas Sauter   +3 more
doaj   +1 more source

Dabrafenib Promotes Schwann Cell Differentiation by Inhibition of the MEK-ERK Pathway

Molecules, 2021
Schwann cell differentiation involves a dynamic interaction of signaling cascades. However, much remains to be elucidated regarding the function of signaling molecules that differ depending on the context in which the molecules are engaged.
Kyuhee Park, Yoonkyoung Shin, Gyeongbeen Lee, Hwantae Park, Yongmun Choi   +4 more
doaj   +1 more source

Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia

Фармакоэкономика, 2023
Objective: to perform a cost-effectiveness analysis of using encorafenib and binimetinib combination in the first-line therapy for metastatic or unresectable BRAF V600-mutated melanoma in the Russian Federation. Material and methods.
N. A. Avxentyev, Yu. V. Makarova
doaj   +1 more source

Chronic Unilateral Uveitis with Macular Edema Secondary to Dabrafenib for Pilocytic Astrocytoma

Case Reports in Ophthalmology, 2021
This report describes a unique case of chronic unilateral anterior uveitis associated with macular edema while on oral dabrafenib treatment for chronic recurrent pilocytic astrocytoma. After gradual taper of prednisolone acetate OS, the patient developed
Matthew Chang, Robin K. Kuriakose, Kunyong Xu, David R.P. Almeida, Eric K. Chin   +4 more
doaj   +1 more source

Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E‐positive non–small cell lung cancer: A case report

Thoracic Cancer, 2023
Dabrafenib plus trametinib is the standard treatment for BRAF V600E‐mutated non‐small cell lung cancer. No treatment‐related cerebral infarction (CI) has been reported in previous clinical trials.
Yoshihiko Taniguchi, Akihiro Tamiya, Atsushi Yanagisawa, Minako Shimaya, Mayu Kawakami, Yuji Inagaki, Nobuhiko Saijo, Yoshinobu Matsuda, Kyoichi Okishio   +8 more
doaj   +1 more source

Successful Dabrafenib Desensitization Protocols in a Patient with Metastatic Melanoma

Medicina, 2022
Dabrafenib and trametinib are two available molecules that have been approved for the treatment of metastatic melanoma with BRAF-V600E or V600K mutations.
Roxana Silvia Bumbacea, Selda Ali, Sabina Loredana Corcea, Dan Corneliu Jinga, Luiza Spiru   +4 more
doaj   +1 more source

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report

BMC Cancer, 2020
Background A BRAF V600E mutation is found as driver oncogene in patients with non-small cell lung cancer. Although combined treatment with dabrafenib and trametinib is highly effective, the efficacy of reduced doses of the drugs in combination therapy ...
Yuta Adachi, Naohiro Yanagimura, Chiaki Suzuki, Sakiko Ootani, Azusa Tanimoto, Akihiro Nishiyama, Kaname Yamashita, Koushiro Ohtsubo, Shinji Takeuchi, Seiji Yano   +9 more
doaj   +1 more source

Dabrafenib: A narrative drug review

Cancer Research, Statistics, and Treatment, 2020
Activating mutations in the BRAF gene lead to an unregulated downstream signaling of the MAPK/extracellular-signal-regulated kinase pathway. This pathway is implicated in a range of solid tumors, and BRAF inhibitors are an attractive option in the ...
Lakhan Kashyap, Saswata Saha, Anne Srikanth   +2 more
doaj   +1 more source

Dabrafenib plus trametinib versus nivolumab for advanced melanoma

Medwave, 2023
Introduction The incidence of cutaneous melanoma has increased worldwide over the years, and an incidence of 3 cases per 100,000 men and women is estimated in Chile.
Daniela Lahoz, Felipe Reyes, Camila Quirland   +2 more
doaj   +1 more source